FDA Warning Letters: What September 2025 Means for GLP-1 Compounders

The FDA fired a warning shot—and 26 compounders were in the crosshairs.

In September 2025, the FDA issued warning letters to 26 compounding pharmacies and telehealth companies for making "false or misleading" claims about compounded GLP-1 medications. The letters represent the agency's most significant enforcement action against the compounded GLP-1 market to date.

But what exactly did these companies do wrong? And what does it mean for patients who use compounded medications?

What FDA Warning Letters Actually Are

First, some context. FDA warning letters are not criminal charges, fines, or product seizures. They're official notifications that the agency believes a company is violating regulations, along with a demand to correct the violations.

What happens after a warning letter:

• Companies have 15 business days to respond with a corrective action plan
• If they comply, the matter typically ends there
• If they don't, FDA can escalate to injunctions, seizures, or criminal prosecution
• Warning letters are public record and can damage company reputation

Think of it as a formal "fix this or else"—serious, but not yet catastrophic.

The Specific Violations Cited

The September 2025 warning letters cited several common violations:

1. "Same As" or "Equivalent To" Claims

The violation: Marketing compounded semaglutide or tirzepatide as "the same as," "equivalent to," or "identical to" Ozempic, Wegovy, Mounjaro, or Zepbound.

Why it's a problem: Compounded medications are NOT FDA-approved. They haven't undergone the testing that proves safety, efficacy, or bioequivalence. Claiming equivalence is both legally and scientifically inaccurate.

Examples cited:

• "Compounded Semaglutide - Same active ingredient as Ozempic®"
• "Get the same results as Wegovy® for less"
• "Our tirzepatide is identical to Mounjaro®"

2. Efficacy Claims Without Evidence

The violation: Claiming specific weight loss percentages, guaranteed results, or clinical outcomes for compounded products.

Why it's a problem: Clinical trial data applies to FDA-approved products under controlled conditions. Compounded products haven't been tested—you can't claim results that weren't studied.

Examples cited:

• "Lose 15-20% of your body weight"
• "Clinically proven weight loss"
• "Same 15% average weight loss as Wegovy®"

3. Understating Risks

The violation: Failing to adequately disclose risks, side effects, or the non-FDA-approved status of compounded medications.

Why it's a problem: Patients deserve accurate risk information to make informed decisions. Hiding or minimizing risks is deceptive.

4. Disease Treatment Claims

The violation: Claiming compounded GLP-1s treat specific diseases (diabetes, cardiovascular disease) without FDA approval for those indications.

Why it's a problem: Only FDA-approved drugs can claim to treat diseases. Compounded products can only be marketed for the specific patient need they're prescribed for.

What Companies Received Letters

FDA doesn't always immediately publish the full list of warning letter recipients, but based on public records, companies cited include a mix of:

• Smaller compounding pharmacies
• Telehealth startups
• Med spas offering weight loss services
• Some larger, well-known telehealth companies

Notably, some major players appeared to avoid warning letters—likely because they had already adjusted their marketing language. The companies that got caught were often the ones with the most aggressive claims.

What Happened After

Following the September 2025 letters:

• Most companies complied: Websites were scrubbed of problematic language within days
• Some pushed back: A few companies contested the violations or sought clarification
• Industry-wide changes: Even companies that didn't receive letters proactively updated their marketing
• No immediate shutdowns: As of early 2026, no companies have been shut down solely based on these warning letters

What Compliant Marketing Looks Like

Companies that avoided or responded to warning letters typically:

• State clearly that compounded medications are NOT FDA-approved
• Avoid comparative claims to brand-name products
• Don't promise specific weight loss percentages
• Include appropriate risk disclosures
• Use language like "compounded semaglutide" rather than "generic Ozempic"
• Emphasize personalization rather than equivalence

What This Means for Patients

Immediate Impact: Minimal

The warning letters targeted marketing, not product availability. If you're currently using compounded GLP-1s from a reputable pharmacy, these letters don't directly affect your access.

What It Signals: FDA Is Watching

The September letters show FDA is actively monitoring the compounded GLP-1 market. This could be a precursor to:

• More aggressive enforcement against non-compliant companies
• Clearer guidance on what compounders can and can't say
• Potential action against companies compounding post-shortage without valid justification

How to Use This Information

When evaluating compounding providers, check if their marketing:

• Claims their product is "the same as" brand medications (red flag)
• Promises specific weight loss results (red flag)
• Clearly states products are not FDA-approved (good sign)
• Discusses personalization rather than equivalence (good sign)

Companies with compliant marketing are more likely to be operating responsibly across the board.

The Bigger Picture

The September 2025 warning letters fit into a broader pattern of increased FDA scrutiny of the compounded GLP-1 market:

• Shortage terminations: Tirzepatide (October 2024) and semaglutide (February 2025)
• Guidance updates: Clarification on "essentially a copy" doctrine
• Manufacturer lawsuits: Novo Nordisk and Eli Lilly suing compounders
• Warning letters: The September 2025 enforcement action

The message is clear: FDA is tightening the regulatory environment around compounded GLP-1s. Companies that don't adapt will face increasing pressure.

The Bottom Line

The September 2025 FDA warning letters were significant but not catastrophic for the compounding industry. They targeted marketing violations, not the practice of compounding itself.

For patients: These letters don't immediately affect your access to compounded GLP-1s, but they're a reminder to choose providers carefully. Look for companies with compliant marketing and transparent practices.

For the industry: The days of wild-west GLP-1 marketing are over. Companies that want to survive need to bring their claims in line with regulatory requirements.

What to watch: How FDA follows up with non-compliant companies, and whether enforcement expands beyond marketing to the legality of post-shortage compounding itself.